Rheumatoid Arthritis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Subjects must meet the 2010 ACR/EULAR rheumatoid arthritis classification criteria and also meet the following inclusion criteria. a. Age >18 years, <80 years, regardless of gender; b. Consent to use effective contraception for the duration of the study (women of childbearing age). c. Patients voluntarily participating in this trial, with the ability to understand and sign an informed consent form prior to the study. d. First diagnosis, moderate-high disease activity (DAS28/CDAI/SDAI), initial treatment recipients. e. No use of hormones, immunosuppressive agents, biologics, etc. at the time of screening.
Exclusion criteria
Exclusion criteria: a. Comorbidity with other rheumatic diseases; b. Combination of other diseases that may cause inflammation of the joints; c. Combination of tumors; d. Those with severe cardiac, hepatic, renal, and other important organ and hematologic and endocrine system pathologies are evaluated according to the following criteria. ? Liver function = 2 times the upper limit of normal value ? Creatinine = 1.5 times the upper limit of normal value ? white blood cell count <3×109/L ? Hemoglobin <80g/L ? Platelet count <60×109/L e. Those who are undergoing acute or chronic infection, or have a previous history of active tuberculosis; f. Those with a history of immunodeficiency, including a positive HIV test, or with other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; g. Positive HBsAb or HCV antibody; h. Those with psychiatric disorders or otherwise unable to cooperate; i. Participating in other clinical trials in the last 3 months; j. Otherwise unsuitable by the investigator;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythrocyte Sedimentation Rate;C-reactive Protein;DAS28;IL-6;TNF-a;MCP-1; | — |
Countries
China